LA CHIMIOTHERAPIE DES SARCOMES OSTEOGENIQUES

Translated title of the contribution: Chemotherapy for osteosarcoma

C. Kalifa, D. Vanel, J. Lemerle

Research output: Contribution to journalArticlepeer-review

Abstract

Functional results and survival have been improved in osteosarcoma during the last ten years, thanks to better conservative surgical techniques and more efficient drugs to prevent metastases. Of the several possible programmes of chemotherapy, the authors considered that the T10 programme of Rosen is the most reliable, this author claiming a survival rate of 90 p. 100 with an average follow-up of twenty months. This programme was adopted by the authors in the Paediatric Department of the Gustave Roussy Institute (Villejuif). Thirty one patients were treated and assessed after an average follow-up of 19 months. The results were favourable, only three patients presenting with metastases. One died. Amongst the thirty surviving patients, twenty-three were treated by local resection and eight by amputation.

Translated title of the contributionChemotherapy for osteosarcoma
Original languageFrench
Pages (from-to)429-434
Number of pages6
JournalRevue de Chirurgie Orthopedique et Reparatrice de l'Appareil Moteur
Volume71
Issue number7
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Surgery

Fingerprint

Dive into the research topics of 'Chemotherapy for osteosarcoma'. Together they form a unique fingerprint.

Cite this